New Genetic Markers Could Predict Which RA Patients Will Respond to Methotrexate

Researchers have identified molecular signatures that predict whether rheumatoid arthritis patients will benefit from methotrexate, one of the most widely used and affordable RA treatments. The finding could help clinicians avoid months of ineffective therapy by identifying non-responders upfront, reducing healthcare costs and improving patient outcomes faster.

Originaltitel: Molecular signature of methotrexate response among rheumatoid arthritis patients